The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to share an important leadership transition within our Board of Scientific Advisors (BOSA), a group of distinguished
Highlights from recent clinical trial developments in neuroendocrine cancer Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly
By Anna C. Greene, PhD, NETRF Chief Scientific Officer One of the most exciting developments in neuroendocrine cancer treatment in recent years has been the
By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we often hear a familiar story: symptoms that don’t
Thank you for your generous support. Because of you, 2025 was a year of meaningful momentum in neuroendocrine cancer research. Through 50 active NETRF-funded projects
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat
By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and
By Udhayvir Singh Grewal, MD, Assistant Professor of Medical Oncology, Emory University School of Medicine Guest Contributor The Annual NANETS Multi-Disciplinary Symposium 2025 was a
Congratulations to Dr. Dawn Quelle, NETRF Board of Scientific Advisors co-chair, and the team at the University of Iowa Health, for winning a $10.7 million
NETRF CEO Elyse Gellerman, Chief Scientific Officer Anna Greene, and Director of Patient Education Jessica Thomas joined hundreds of neuroendocrine cancer specialists and patient advocates